Muhammad Fiaz Khalid1, Kanwal Rehman2, Kanwal Irshad1, Tahir Ali Chohan3, Muhammad Sajid Hamid Akash1. 1. Department of Pharmaceutical Chemistry, Government College University, Faisalabad, Pakistan. 2. Department of Pharmacy, The Women University, Multan, Pakistan. 3. Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan.
Abstract
The aim of current study was to investigate the inhibitory activities of resveratrol and taxifolin against α-amylase, α-glucosidase, and DPP-IV enzymes via in vitro analysis which was further validated by in silico studies. The analysis of molecular docking was also done to determine the binding capabilities of resveratrol and taxifolin with α-amylase, α-glucosidase, and DPP-IV enzymes. Resveratrol and taxifolin having IC50 values, 47.93 ± 5.21 μ M and 45.86 ± 3.78 μ M , respectively, showed weaker effect than acarbose (4.6 ± 1.26 μ M ) on α-amylase but showed significant effect to inhibit α-glucosidase (32.23 ± .556 μ M and 31.26 ± .556 μ M , respectively). IC50 value of resveratrol and taxifolin (5.638 ± .0016 μ M and 6.691 ± .004 μ M ) in comparison to diprotin A (IC50: 7.21 ± .021 μ M ) showed that they have significant inhibitory effect on DPP-IV enzyme. Our results illustrated that resveratrol and taxifolin have potential to prevent the metabolism of carbohydrates via inhibition of α-amylase and α-glucosidase, and prolongs metabolic function of incretin by inhibiting the enzymatic activity of DPP-IV. The results of molecular docking have also revealed that resveratrol and taxifolin have significant affinity to bind with α-amylase, α-glucosidase, and DPP-IV in comparison with standard drugs such as acarbose, miglitol, and diprotin.
The aim of current study was to investigate the inhibitory activities of resveratrol and taxifolin against α-amylase, α-glucosidase, and DPP-IV enzymes via in vitro analysis which was further validated by in silico studies. The analysis of molecular docking was also done to determine the binding capabilities of resveratrol and taxifolin with α-amylase, α-glucosidase, and DPP-IV enzymes. Resveratrol and taxifolin having IC50 values, 47.93 ± 5.21 μ M and 45.86 ± 3.78 μ M , respectively, showed weaker effect than acarbose (4.6 ± 1.26 μ M ) on α-amylase but showed significant effect to inhibit α-glucosidase (32.23 ± .556 μ M and 31.26 ± .556 μ M , respectively). IC50 value of resveratrol and taxifolin (5.638 ± .0016 μ M and 6.691 ± .004 μ M ) in comparison to diprotin A (IC50: 7.21 ± .021 μ M ) showed that they have significant inhibitory effect on DPP-IV enzyme. Our results illustrated that resveratrol and taxifolin have potential to prevent the metabolism of carbohydrates via inhibition of α-amylase and α-glucosidase, and prolongs metabolic function of incretin by inhibiting the enzymatic activity of DPP-IV. The results of molecular docking have also revealed that resveratrol and taxifolin have significant affinity to bind with α-amylase, α-glucosidase, and DPP-IV in comparison with standard drugs such as acarbose, miglitol, and diprotin.
Diabetes mellitus (DM) is a metabolic disorder which is characterized by
hyperglycemic state for a prolonged period due to abnormal insulin secretion and function.
WHO (World Health Organization) has reported 3.2 million deaths due to DM.
The major risk factors for the occurrence of DM include life style, high
intake of calories, genetic predisposition, and obesity.
For the treatment of DM, typically anti-diabetic drugs possessing different
mechanism of action are known but these drugs have some serious side effects such as
weight gain, nutritional disorders, hypoglycemia, allergic reactions, and liver damage.
These side effects have gained the attention of researchers to discover the
novel anti-diabetic agents having less side effects. Present research leads to the
development of therapeutic agents which have more than one therapeutic target to
achieve the adequate level of blood glucose.Carbohydrates are the main source of energy for animals and human beings which are
digested by α-amylase which is a hydrolase that cleaves 1,4-glucosidic bond in the
linear regions in starch, glycogen and in various other different types of
disaccharides and oligosaccharides. The hydrolytic action accompanied by α-amylase
converts complex carbohydrates into simple monosaccharide (glucose units).[6,7] Similarly,
hypothalamus-pituitary-adrenal axis converts them into simple sugars and facilitates
the absorption of monomers of sugars from intestine into the blood stream
that ultimately produces hyperglycemia and various other types of metabolic disorders.
The suppression of human α-amylase (HPA) and α-glucosidase (GLU) activities
results in less availability of individual monomers of absorbable sugars which
ultimately decreases the postprandial hyperglycemia.[8,9] It has been well-documented
that plant-derived bioactive compounds may inhibit the enzymatic activity of HPA
reversibly and competitively to maintain the glycemic status within the
body.[7,10,11] In diabetic
patients, incretin-based treatment proved helpful in decreasing the incidence of hyperglycemia.
Upon the uptake of nutrients, intestinal enteroendocrine cells release
incretins and peptide hormones which stimulate the secretion of insulin.
It has been observed that incretin hormones such as glucose-dependent
insulin-tropic (GIP) and polypeptide i.e., glucagon-like peptide-1 (GLP-1) are
involved in stimulating the secretion of insulin depending upon the level of glucose
in healthy individual. After the secretion of GLP-1 and GIP, they are transformed
into inactive metabolites via cleavage of N-terminal alanine or
praline.[14,15] The half-life of these hormones is about 2 minutes. They are
rapidly degenerated by dipeptidyl peptidase IV (DPP-IV).
GLP-1 is regarded as the most important substrate of DPP-IV enzyme. The
nutrient dependent secretion of GLP-1 can induce the release of insulin from β-cells
of pancreatic islets in order to regulate the glycemic status of the body. However,
DPP-IV rapidly degrades GLP-1 due to which it performs its action for a short period
of time. Hence, DPP-IV inhibition increases the level of insulin in systemic
circulation by inhibiting the degradation of GLP-1.
This phenomenon leads to decrease the elevated level of blood glucose. This
is the most important therapeutic intervention and target that leads the researcher
for the development of DPP-IV inhibitors in order to alleviate the glucose burden in blood.Resveratrol (RSV) is a polyphenolic compound belonging to a class of stilbenes and
found in many food products and fruits.
RSV has a potential to reduce the oxidative stress, increases insulin
sensitivity, and restores the insulin signaling pathway which ultimately improves
the glucose metabolism.
The reduction in oxidative stress improves the insulin signaling pathway and
enhances the insulin sensitivity.
RSV alters the expression of adipokines by inhibiting the inflammatory
response and reduces the resistance of insulin via activation of sirtuins 1 (SIRT1),
principal modulator of to regulate insulin sensitivity and glucose homeostasis.22RSV ameliorates the glycemic status and blood glucose level in type 2 diabetic patients.
Thus, supplementation of RSV in diabetic patient improves the glycemic
status, HbA1c level, cholesterol, and systolic pressure.
The literature showed that RSV has been used in the treatment of diabetes
owing to its antioxidant action. It can also ameliorate the insulin resistance
especially in primary human adipocytes.
Taxifolin (TAX) is another naturally occurring flavonoid having potential to
reduce the oxidative stress which is induced by hyperglycemic states by the
inhibition of recombinant aldose reductase and sorbitol.
TAX has antioxidant potential to protect the vascular tissues and heart
against the oxidative stress and lipid peroxidation. TAX has significant role in
reducing the apoptosis incidence.
It also has a significant role to inhibit the activity of α‐amylase and
ultimately decrease the rate of metabolism of carbohydrates which leads to lower the
level of glucose in systemic circulation. TAX reduces the glucose level which is
induced by osmotic stress via reduction of sorbitol and aldose
reductase in human. Recently, it has proved that TAX protects the vascular tissues
and heart by providing the protection against the lipid peroxidation and by reducing
the apoptosis incidence.
Therefore, it is important that inhibitors of carbohydrate metabolizing
enzymes may be one of the choices of therapeutic interventions for the treatment of
postprandial hyperglycemia. Molecular docking is an efficient and highly accurate
prediction strategy for the identification of the structures of protein–ligand
complexes, which are helpful in computations for recognition of molecules especially
for designing of drug molecule.
It considers all the factors including active site of receptors, small
molecular structure, ligand binding, and determines the low-energy binding modes.
For the development of cost-effective and alternative anti-diabetic drugs,
there is need to determine the routes to decrease the production of enzymes that are
involved in the digestion of carbohydrates.The aim of current study was to investigate the in vitro
characterization of RSV and TAX against carbohydrate metabolizing enzymes.
Furthermore, we performed molecular docking in order to get the information about
the molecular aspects of these compounds. In this study, we determined in
vitro carbohydrates and incretin metabolic enzymatic activity of RSV
and TAX to identify and confirm the glucoregulatory mode of action of these
polyphenolic compounds. The inhibitory assays along with kinetic studies were
performed for the evaluation of inhibitory potential and binding modes of RSV and
TAX with α-amylase, α-glucosidase, and DPP-IV assay kits. We validated our
hypothesis via molecular docking of RSV and TAX with these enzymes
via standard inhibitors acarbose (ACB), miglitol (MGL), and
diprotin A (DPT), respectively.
Materials and Methods
Materials Required
Resveratrol (CHEM-IMPEX INT’L INC), taxifolin (Sigma aldrich), acarbose
(Carbosnyth,USA), diprotin (Sigma aldrich), HPA assay kit (Product code: K-CERA,
Megazyme brand), α-glucosidase assay kit (Product code: MAK123, Sigma aldrich),
DPP-IV inhibitor screening assay kit (Product code: ab133081 Abcam), starch
(Sigma aldrich) and all the other materials of analytical grade were used.
In vitro Inhibitory Activity of Bioactive Compounds Against
α-glucosidase
The mixture of 17 μL of 5 mM pNPG (4, nitrophenyl α-D-glucopyranoside) and 5 μL
of RSV and TAX solutions, with different concentrations (0, 10, 25, 50, 75, and
100 μM), were incorporated into 96 well microplate.
Afterwards, this mixture was incubated for 5 min at 37 °C. After performing
incubation, 17 μL of .15 μg/mL GLU solution was put in each well microplate.
Again, the mixture was incubated till the end of hydrolytic reaction. After 15
min, 100 μL of 200 mM solution of sodium carbonate was incorporated into each
well microplate to block the proceeding of reaction. At the end, the absorbance
was calculated at 405 nm by employing a microplate reader. The results of GLU
activity were presented in IC50 as described previously.The method of linear regression equation was adopted to calculate the
IC50 accompanying a graph showing the concentration of sample on
x-axis while % inhibition on y-axis. By
employing equation of linear regression, that is, y =
a + bx, the values of IC50 were
calculated
In vitro Inhibitory Activity of Bioactive Compounds Against
α-amylase
Around 250 μL of bioactive compounds (RSV and TAX) of different concentrations
(0, 10, 25, 50, 75, and 100 μg/mL), 2% (w/v) starch, and 250 μL of 1 U/mL HPA
solution were mixed homogenously in test tube. The mixed solution was incubated
at 20 °C for 3 min. After incubation, 500 μL of dinitro salicylic acid (colored
reagent) was added in each well to stop the enzymatic reaction. Then mixture was
put into boiled water and 250 μL of HPA1 U/mL was added immediately. The mixture
was heated continuously for 15 min and then allowed to cool at room temperature.
To make the total volume of solution up to 6000 μL, 4500 μL of distilled water
was added into the solution and mixed well using a vortex mixer. The activity of
HPA was calculated by measuring the absorbance at 540 nm via spectrophotometry.
The absorbance of product was compared with blank solution. The % inhibition was
calculated by using equation.
The data obtained from HPA activity was used for determination of %
inhibition by using following equation
where A1 is absorbance of blank and A2 is absorbance of sample.
These results were processed in the form of graph and compared with % inhibition
of ACB as positive control. The value of IC50 was calculated by
following the same procedure as described above.
In vitro Inhibitory Activity of Bioactive Compounds Against
DPP-IV
The in vitro gastrointestinal digestion model was established by
following the instructions and protocols as described previously.
The inhibitory activity of bioactive compounds against DPP-IV in the
existence of Gly-Pro-AMC with a concentration range of 0 to 60 μM was carried
out by following the instructions of assay reagent kit’s manufacturer as
described previously and presented in terms of IC50.
Inhibitory Kinetics Study of Bioactive Compounds
The inhibitory actions of RSV and TAX against carbohydrate metabolizing were
determined at 0.25 and 0.5 mg/mL, separately. Each sample of different
concentrations was estimated in the existence of Gly-Pro-AMC with various
concentrations (0–60 μM). The pattern of inhibition was determined by employing
Lineweaver-Burk plot. The constant (K
) which is known as inhibition constant was calculated
with help of a graph showing a reciprocal relationship with initial luminescence
and substrate.
Computational Study and Molecular Docking of Bioactive Compounds
Structural preparation and docking studies
The co-crystal structure of carbohydrate metabolizing enzymes such as human
α-amylase (HPA) and DPP-IV were obtained from data bank of RCB protein with
entries such as 1HNY (HPA) and 4A5S (DPP-IV). For protein modeling, Phyre2
online server was used to develop the 3D structure of GLU.
The FASTA sequences having NCBI Accession no P07265 were obtained
from uniprot.
The 3D-macromolecular structure with maximum Phyre2 confidence score
was downloaded and carefully analyzed to avoid any stereo-chemical
deformity. In order to predict the quality of Phyre2 generated protein
structure, Psi/Phi Ramachandran plot was generated by submitting
3D-conformation of GLU into the PROCHECK webserver.
Furthermore, the ProSAweb web tool
was utilized to compute empirically derived Z-scores to countercheck
the quality of generated structural model. Likewise, the co-crystalized
structures of 1HNY and 4A5S were also carefully inspected by employing
SYBYL-X 1.3 module to authenticate chemical accuracy.
Missing hydrogens were computationally added. The appropriate charges
and atoms were employed as recommended by AMBER7FF99 force field,
accompanied by a loss of energy by employing Powell algorithm
with .5 kcal/(mol•Å) convergence gradient followed by 1000 cycles.
The Figure 1 is
showing the 3D-structures of bioactive ligands accompanying with standard
inhibitors such as miglitol (MGL), acarbose (ACB), and diprotin (DPT) of
carbohydrate metabolizing enzymes. The structures were built by using SKETCH
module implemented in Sybyl-X1.3.
The energy optimization of generated 3D-conformations of TAX, RSV,
ACB, MGL, and DPT was performed as suggested by Tripos force field with
Gasteigere Huckel atomic charge. Finally, the compounds TAX, RSV, ACB, MGL,
and DPT were docked with their particular targets by employing Surflex-Dock
(flexible) SYBYL-X 1.3 module
molecular modeling software package to get insight into the binding
modes of tested compounds bonded to HPA, GLU, and DPP-IV enzymes. Top twenty
docking generated putative poses were saved for each inhibitor. SYBYL
utilizes the Hammerhead scoring (cScore) function[40,44] to
rank putative poses of ligands in their corresponding complexes. All
settings for Surflex-Docking were kept same as mentioned in our study.
Figure 1.
Chemical structures of selected ligands for molecular docking
analysis. (A) Chemical structures of tested compounds taxifolin
(TAX) and resveratrol (RSV). (B) 2D-structural representation of
standard compounds acarbose (ACB), miglitol (MGL), and diprotin
(DPT). (C) Supposed conformation of selected hits and standard
compound in their corresponding molecular targets.
Chemical structures of selected ligands for molecular docking
analysis. (A) Chemical structures of tested compounds taxifolin
(TAX) and resveratrol (RSV). (B) 2D-structural representation of
standard compounds acarbose (ACB), miglitol (MGL), and diprotin
(DPT). (C) Supposed conformation of selected hits and standard
compound in their corresponding molecular targets.
Molecular dynamics simulation studies
The structural models of complexes of TAX and RSV bonded to HPA, GLU, and
DPP-IV, as exhibited in Figure 1C, were processed by employing MD simulation strategy in
order to inspect their structural behaviors. The MD-simulations were
accomplished with the help of AMBER-16 software
along with ff99SB force field.
Likewise, docking complexes of standard compounds as exhibited in
Figure 1C
bonded to their respective molecular targets (ACB-HPA, MGL-GLU, and
DPT-DPP-IV) were also subjected to MD-simulation. Moreover, a comparison
between binding free energies of TAX- and RSV-enzyme complexes with standard
compounds, that is, ACB, MGL, and DPT-bonded systems were investigated by
employing the approach of MM/PB(GB)SA.
All MD simulations and binding free energies (MM/PB(GB)SA) were
computed with AMBER16 software package,
by employing same strategy as mentioned in our previous
work.[9,45]
Statistical analysis
The results of in vitro study are expressed as mean
SD (standard deviation) (n = 6) by using Graph pad prism.
The results were statistically analyzed by employing One-Way ANOVA followed
by a post hoc test known as Dunnett’s test. The value of P<.05 was
considered as significant.
Results
We measured the in vitro inhibitory activities of various
concentrations of RSV and TAX against α-glucosidase, α-amylase, and DPP-IV. We also
investigated the inhibitory activity of each concentration of RSV and TAX
accompanying Gly-Pro-AMC (0–60 μM) in various concentrations and exhibited the
in vitro % inhibition against carbohydrate metabolizing enzymes
with IC50 values as shown in Table 1. Both bioactive compounds
exhibited their inhibitory activity against DPP-IV more significantly as compared to
that of their positive control.
Table 1.
Inhibitory Activity of Bioactive Compounds Against GLU, HPA, and DPP-IV
Enzymes.
Parameters
α-glucosidase
α-amylase
DPP-IV
DPP-IV
IC50(μM)±SD
IC50(μM)±SD
IC50(μM)±SD
Ki(μM)
Positive control l (Diprotin A)
-
-
7.21 ± .021
7.32
Positive control l (Acarbose)
4.6 ± 1.26
77.88 ± .277
-
10.76
Resveratrol (RSV)
47.93 ± 5.21
32.23 ± .556
5.638 ± .0016
14.96
Taxifolin (TAX)
45.86 ± 3.78
31.26 ± .556
6.691 ± .004
12.31
Abbreviations: IC50; inhibitory concentration is
measure at the half maximal, SD; standard deviation,
; inhibition constant.
Inhibitory Activity of Bioactive Compounds Against GLU, HPA, and DPP-IV
Enzymes.Abbreviations: IC50; inhibitory concentration is
measure at the half maximal, SD; standard deviation,
; inhibition constant.The in vitro inhibitory effect of bioactive compounds (RSV, TAX)
on enzymatic activity of GLU was measured by using pNPG as substrate while
acarbose used as positive control. Based on IC50 values, we affirmed
that RSV and TAX has inhibitory effect on GLU with IC50 (47.93±5.21
and 45.86 ± 3.78
), respectively. But these compounds have weak inhibiting
effect on GLU as compared to acarbose IC50 (4.6 ± 1.26
) as shown in Table 1.The in vitro inhibitory effect of RSV and TAX on enzymatic activity of HPA was
measured by using starch as substrate while acarbose was used as positive
control. RSV and TAX have IC50 value 32.23 ± .556 μM and 31.26 ±
.556 μM, respectively, showing that higher significant effect in comparison to
acarbose (IC50: 77.88 ± .277 μM) as exhibited in Table 1. However, RSV
and TAX have approximately same inhibitory effect on HPA enzyme.The in vitro inhibitory activity of RSV and TAX on enzymatic
activity of DPP-IV was investigated using diprotin A was used as positive
control. The result was concluded based on IC50 values, RSV and TAX
have strong inhibitory effect showing IC50 value (5.638 ± .0016
and 6.691 ± .004 ), respectively, in comparison to diprotin A
(3.21 ± .021
).
Molecular Docking of Bioactive Compounds
The outcomes of in vitro studies demonstrate that TAX and RSV
exhibit the remarkable binding affinity towards HPA, GLU, and DPP-IV enzymes as
compared to their benchmark inhibitors; ACR, MGL, and DPT, respectively. In
order to compare the interaction pattern of tested compounds and the standard
inhibitor of GLU, 3D structure of GLU was modeled followed by molecular docking
studies as exhibited in figure
1B. The best phyre2 predicted structure of GLU according to Phyre2
confidence (93%) was selected for further processing. The findings of
empirically derived Z-score and Ramachandran plot (Figure 2) further
supported the reliability and accuracy of our modeled structure. The
Ramachandran plot for GLU protein depicts that 99.2% of residues lie in the
allowed region including 88.2% in most favored region. Furthermore, appreciable
values of Z-score (−10.58) also suggest that the quality
modeled structure is good enough to be used for docking analysis.
Figure 2.
Ramachandran Plot analysis performed with PROCHECK online webserver
and ProsWeb generated Z-score graph.
Ramachandran Plot analysis performed with PROCHECK online webserver
and ProsWeb generated Z-score graph.In this study, MD simulation studies were carried out to identify the variations
in binding mode studied ligands in their complexes, which may explain the
difference in the affinities of ligands towards target proteins. The top-ranked
docking generated conformations according to cumulative score
(cScore) were selected as shown in Table 2. The scores of TAX, ACB, and
RSV for HPA were 7.82, 7.22, and 6.90, respectively, and these scores indicated
that TAX had almost same affinity towards HPA as that of ACB. Although, RSV
demonstrated slight less binding affinity among three HPA-bonded systems, the
binding affinity still reflects that RSV is tightly bonded to HPA. In DPP-IV
bonded system, TAX and RSV exhibited the significant affinity (cScore: 5.43 and
5.54, respectively) towards DPP-IV as compared to standard inhibitor such as DPT
(cScore: 4.26). Both studied hits of bioactive compounds showed the decreased
values of cScore in GLU-bonded systems as compared to GLU-MGL system. However,
there was no significant variation between the Score of GLU-TAX and GLU-MGL
suggesting the binding affinity of TAX towards GLU is comparable to that of
GLU-MGL system. The docking scores accompanying a list of residues contributing
H-bonding are summarized in Table 2. The top-ranking docking
generated putative poses of studied hits were saved and viewed graphically in
biopolymer module (SYBYL-X 1.3) in order to determine the possible variations in
the interaction pattern of different ligands bonded to same molecular target as
exhibited in Figure 3.
Furthermore, the simple 2D receptor-ligand diagram showing the interaction of
whole docking pose as exhibited in Figure 4 give more detailed insight into
variations in the mode of ligand-receptor interactions.
Table 2.
Surflex Score of Docked Ligands; Taxifolin and Resveratrol for GLU,
HPA, and DPP-IV Along With Their Corresponding Standard Molecules
Acarbose, Miglitol, and Diprotin A.
Protein
Ligands
CScore
Crash score
Polar score
G score
PMF score
D score
Chem score
Amino acid interaction
α-amylase
Acarbose
7.22
−3.27
6.36
−204.817
−10.715
−162.326
3.965
D300, E233, H201, K200
Resveratrol
6.90
−1.11
4.98
−159.609
−16.661
−92.326
−17.170
R195, D197, D300, H299
Taxifolin
7.82
−.94
4.14
−208.162
−42.372
−119.501
−13.290
Q63, E233, R199, D197, H299
α-glucosidase
Miglitol
4.95
−.95
6.40
−68.447
−31.476
−724.892
−7.277
D91, W126
Resveratrol
4.17
−.60
4.01
−120.570
−7.402
−96.736
−10.412
R331, C127, W126, D91, I98, A93
Taxifolin
4.74
−1.03
4.02
−88.053
2.091
−84.855
−10.702
P94, I98, R331, D91, W126, C127
DPP-IV
Diprotin
4.26
−1.14
2.67
−161.702
−37.837
−112.472
−11.725
Y547, E205, S630, H740, N710
Resveratrol
5.54
−1.45
4.28
−105.239
24.386
−70.525
−18.476
Y547, R669, E206, V207, R358
Taxifolin
5.43
−.89
6.01
−143.571
20.390
−66.641
−17.637
Y547, E206, R669
Figure 3.
Docking generated complexes of enzymes; HPA, GLU, and DPP-IV bonded
to their standard inhibitors and tested compounds: (A) ACB-HPA (B)
TAX-HPA (C) RSV-HPA, (D) MGL-GLU (E) TAX-GLU (F) RSV-GLU (G)
DPT-DPP-IV (H) TAX-DPP-IV (I) RSV-DPP-IV.
Figure 4.
The diagram of 2D-ligand-protein interaction was retrieved in order
to obtain best poses with ACB (A) and TAX (B) and RSV(C) against AML
crystal structure. Ligands bonded to GLU enzyme are depicted in (D)
MGL (E) TAX and (F) RSV. DPP-4 bonded complexes are (G) DPT (TAX)
and (RSV). The H-bonding is represented via green and blue dotted
arrows as H-bond donor/accepter pattern, respectively.
Surflex Score of Docked Ligands; Taxifolin and Resveratrol for GLU,
HPA, and DPP-IV Along With Their Corresponding Standard Molecules
Acarbose, Miglitol, and Diprotin A.Docking generated complexes of enzymes; HPA, GLU, and DPP-IV bonded
to their standard inhibitors and tested compounds: (A) ACB-HPA (B)
TAX-HPA (C) RSV-HPA, (D) MGL-GLU (E) TAX-GLU (F) RSV-GLU (G)
DPT-DPP-IV (H) TAX-DPP-IV (I) RSV-DPP-IV.The diagram of 2D-ligand-protein interaction was retrieved in order
to obtain best poses with ACB (A) and TAX (B) and RSV(C) against AML
crystal structure. Ligands bonded to GLU enzyme are depicted in (D)
MGL (E) TAX and (F) RSV. DPP-4 bonded complexes are (G) DPT (TAX)
and (RSV). The H-bonding is represented via green and blue dotted
arrows as H-bond donor/accepter pattern, respectively.
Molecular Dynamic Simulation Studies
All the 9 docking complexes; ACB-HPA, TAX-HPA, RSV-HPA, MGL-GLU, TAX-GLU,
RSV-GLU, DPT-DPP-IV, TAX-DPP-4, and RSV-DPP-IV were subjected to MD simulations
to identify the molecular interactions. All of nine complexes were
post-processed with MD simulations for 30 ns and the RMSD (root-mean-square
deviation) was computed during the entire simulation time to elucidate the
stability of studied complexes in solution. As depicted in Figure 5, all complex systems retained
their structural conformation intact and stable throughout the simulation period
while the RMSD values remained below 2.5 Å for protein, pocket, or
ligand. Among all 3 complexes, the least RMSD was found to
be displayed by TAX in HPA-TAX bonded system (Figure 5B), which confirms that the
ligand TAX is tightly complexed with HPA. The highest value of docking scores
also supports these findings as depicted in Figure 6, all the ligands remained
intact in its complex form without any loss of key interactions.
Figure 5.
RMSDs of Cα atoms of the protein, backbone atoms of binding pocket
(within 6.5 Å), and the heavy atoms in the ligand for: (A) ACB-HPA
(B) TAX-HPA (C) RSV-HPA, (D) MGL-GLU (E) TAX-GLU (F) RSV-GLU (G)
DPT-DPP-IV (H) TAX-DPP-IV (I) RSV-DPP-IV.
Figure 6.
Structure comparison between initial (green) and representative
snapshots from MD (slate) of: (A) ACB-AML (B) TAX-AML (C) RSV-AML,
(D) MGL-GLU (E) TAX-GLU (F) RSV-GLU (G) DPT-DPP-IV (H) TAX-DPP-IV
(I) RSV-DPP-IV.
RMSDs of Cα atoms of the protein, backbone atoms of binding pocket
(within 6.5 Å), and the heavy atoms in the ligand for: (A) ACB-HPA
(B) TAX-HPA (C) RSV-HPA, (D) MGL-GLU (E) TAX-GLU (F) RSV-GLU (G)
DPT-DPP-IV (H) TAX-DPP-IV (I) RSV-DPP-IV.Structure comparison between initial (green) and representative
snapshots from MD (slate) of: (A) ACB-AML (B) TAX-AML (C) RSV-AML,
(D) MGL-GLU (E) TAX-GLU (F) RSV-GLU (G) DPT-DPP-IV (H) TAX-DPP-IV
(I) RSV-DPP-IV.
MM/PB(GB)SA
Finally, a comprehensive analysis of computed binding free energies of TAX and
RSV towards HPA, GLU, and DPP-IV enzymes was conducted by applying MM/PB(GB)SA
approach. The same approach using aforementioned protocols and parameters was
utilized to measure the binding affinities of standard inhibitors; ACB, MLG, and
DPT bonded to their respective molecular targets; HPA, GLU, and DPP-IV. The
obtained values of binding free energy terms for standard-enzyme complexes and
TAX- and RSV-enzyme complexes were graphically depicted to individually compare
the binding affinities of ligand-protein complexes with each other as exhibited
in Figure 7. The
calculation of binding free energy ΔGpred(GB) on the basis of
MM/PB(GB)SA exhibits that both compounds TAX and RSV (−29.85 kcal/mol;
−18.92 kcal/mol, respectively) are entrapped within HPA-binding cleft as
compared to standard compound (−11.25 kcal/mol). Since, TAX demonstrates the
highest variations in the values of ΔGpred(GB) for HPA as compared to
ACB and RSV, providing an indication that the TAX has highest selectivity
towards HPA as compared to other compounds (Figure 7A). Likewise, the calculation of
binding free energies on the basis of MM/PBSA also exhibits the variations in
pattern of binding affinities, providing an indication that TAX and RSV show
equal potential towards HPA (ΔGpre(PB) −19.68 kcal/mol;
−19.84 kcal/mol, respectively) than ACB (ΔGpre(PB)
−8.93 kcal∙mol−1). Similarly, in GLU-bonded systems RSV and TAX
demonstrates slightly better binding affinities (ΔGpre(PB) −34.60 and
−31.32 kcal∙mol−1) for GLU than the corresponding value
(ΔGpre(PB) −29 kcal∙mol−1) of MGL-GLU system (Figure 7B). Among
DPP-IV-ligand systems, again compound TAX displayed even superior binding
affinities (ΔGpre(PB) −8.93 kcal∙mol−1) than the standard
compound DPP (ΔGpre(PB) −40.33 kcal∙mol−1). Although,
compound RSV shares least binding affinity among studied DPP-IV-bonded systems
as exhibited in Figure
7C, the difference in binding affinities is not too high indicating
that RSV is also tightly bonded to DPP-IV.
Figure 7.
Comparison among free energy terms of: (A) HPA linked to ACB, TAX,
and RSV; (B) GLU linked to MGL, TAX and RSV; (C) DPP-IV linked to
DPT, RAX, RSV.
Comparison among free energy terms of: (A) HPA linked to ACB, TAX,
and RSV; (B) GLU linked to MGL, TAX and RSV; (C) DPP-IV linked to
DPT, RAX, RSV.
Discussion
HPA is involved in the digestion of carbohydrates. It breaks down the
α-(1,4)-glycosidic bonds of oligosaccharides during the formation of bolus and
swallowing of food.
The inhibition of HPA has significant role in suppressing the postprandial
hyperglycemia which in turn slows down the carbohydrate digestion and reduces the
absorption of glucose into the blood stream. Similarly, the inhibitors of GLU enzyme
are obtained from various plant-based sources that suppress the hydrolysis of
oligosaccharides. As a result, the release of α-glucose is diminished along with
retardation in the digestion of carbohydrates and glucose absorption in the small
intestine. This mechanism has significant role in maintaining the postprandial
hyperglycemia and considered as novel therapeutic approach for the stabilization of
blood glucose status in diabetic patients.
DPP-IV inhibitors are currently used as antihyperglycemic agents that block
the enzymatic activity of DPP-IV which is a serine protease present in the
endothelial layer of blood vessels, kidneys, and gastrointestinal tract. They
deactivate the insulinotropic polypeptide, incretin, and GLP-1, which are considered
essential for the secretion of insulin from pancreatic β-cells and suppression of
pancreatic glucagon secretion.[52,53] Commercially available GLU
inhibitors are non-selective drugs that also inhibit the pancreatic HPA leading to
serious gastrointestinal side effects which is a major drawback of GLU inhibitors.
Therefore, there is an utmost need to discover and develop new drugs having
strong GLU inhibitory activity but mild potential to inhibit pancreatic HPA activity.
Many polyphenols have ideal structural attributes including hydrophobic
nature, flexible backbone, and several hydrogen bond donor and acceptor. By keeping
in view these attributes, we selected two polyphenols, RSV and TAX for evaluation of
percentage inhibitory activity against carbohydrate (GLU and HPA) and GLP-1
metabolizing for RSV and TAX, separately. Many methods are available for the
enzymatic assays
but we employed in vitro and in silico approaches for initial screening and
comparison among selected bioactive compounds.The In vitro activity of RSV and TAX has affirmed that both
bioactive compounds have significant inhibitory potential as shown in Table 1. The % inhibition
at various concentrations of RSV and TAX exhibited that inhibition percentage
depends upon the concentration. RSV and TAX have high HPA inhibitory activity as
compared to that of positive control (acarbose). Both bioactive compounds can
exhibit high inhibitory activity than the acarbose even in smaller concentration.
The results of our experiments with respect to GLU are inconsistent with reported study.
While, TAX inhibits GLU activity in a competitive manner.
The literature showed that dietary polyphenols including RSV have GLU
inhibitory activity and used as supplementation for the treatment of diabetes as
anti-diabetic agents.
Our study confirmed that RSV and TAX have the potential to inhibit the
enzymatic activity of GLU that may lead to lower the postprandial hyperglycemia and
potentially inhibit the intestinal GLU activity. Inhibition of GLU activity is
prominent mechanism in contributing the anti-diabetic activity. We also determined
the in vitro inhibitory activity of RSV and TAX against HPA as
exhibited in Table 1.
HPA cleaves the glycosidic bond in starch, but RSV and TAX inhibit the activity of
α-amylase. Due to this mechanism of action, starch cannot form the disaccharides in
body. HPA facilitates GLU for conversion of disaccharides into monosaccharides and
maintains the level of glucose.
Our study confirmed that RSV and TAX inhibit GLU and HPA enzymes and help to
regulate the metabolism of carbohydrates and hyperglycemic status. Our results are
in consistent with already published data showing that RSV has potential to inhibit GLU,
as well as TAX also has GLU inhibitory activity as previously reported.
Our results regarding the inhibition of HPA by RSV and TAX are supported by
published data.[9,62] RSV and TAX can inhibit DPP-IV to regulate the glucose
homeostasis. TAX inhibits DPP-IV with less activity with high IC50 value
as compared to RSV. Our results regarding DPP-IV inhibitory effects by RSV and TAX
are in accordance with published data.[63,64] The docking technique is
utilized to investigate the interactions between small molecule and protein at
atomic level to predict the binding behavior of small molecules toward protein along
with elucidation of fundamental biochemical processes. Two main steps are involved
in docking: to predict the conformation, position, and orientation of ligand and
estimate the binding affinity of ligand.
The prediction of electronic characteristics which replicated our
experimental results was measured by top ranked docked poses of HPA-TAX and -RSV
complexes. The MD simulations have strong impact in the field of molecular biology
as well as drug discovery. These simulations are helpful to analyze and understand
the behavior of biomolecules and proteins at atomic level with fine temporal resolution.The best docking conformations were saved for each compound and investigated to
explore the differences in ligand-protein interactions patterns accounting for
difference in binding affinities of ligands to its target protein as exhibited in
Figure 3. As shown in
Figure 1C and 3A-C, all three ligands adopt
similar pattern of interaction within the binding cavity of HPA to develop H-bond
contacts with surrounding residues. In HPA-ligand bonded systems, W58, W59, T62,
Q63, H101, L162, L165, R195, D197, A198, G233, I235, F256, H299, D300, H305, G306,
and A307 are the key amino-acids constituting the active site of HPA. The best
docked model of ACB-HPA complex, as exhibited in Figure 3A, reveals that the ACB
predominantly occupies the binding site of HPA to establish eight H-bond contacts
with nearby residues such as Q63, Y153, T163, K200, H201, E233, H299, and D300.
Interestingly, E233 and D300 are more crucial as these are involved in the
hydrolysis of carbohydrates. These residues have been investigated in order to
detect their interactions with ethyl caffeate and myricetin,
which authenticates the rationality of docking results. In order to elucidate
the interaction pattern of TAX and RSV with HPA, the top ranked docked poses of
HPA-TAX and -RSV complexes were also evaluated critically exhibited in Figure 3B and C. The results
of molecular docking exhibits that various residues involving in HPA-ACB
complexation also contribute to form TAX and RSV-HPA complex system. However, unlike
ACB-HPA system, TAX establishes only three H-bond interactions Q63, R195, and E233
of HPA is unable to interact with TAX. Similarly, RSV also establishes a set of
triple H-bond interactions with residues T163, R195, and D300.However, it was not surprising as TAX and RSV exhibit smaller structural dimensions
as compared to ACB. Both rings of TAX designated as A and B extend in a reverse way
in cleft (ligand binding) of HPA, where they can also establish π-π interaction with
Tyr62 and Trp59 as exhibited in Figure 2B. However, this type of interaction was not observed in
acarbose based RSV and HPA system because acarbose lack aromatic ring as shown in
Figure 1 and 2B. Despite of greater number
of H bond interaction in ACB-HPA system, the better binding affinity of TAX in is
mainly attributed by the other non-bonding interactions. Thus, the fluctuations in
interaction pattern of ligand-receptor can increase the HPA inhibitory potential of
TAX as compared to RSV and ACB. The top-ranked docking generated conformations for
GLU-bonded systems (GLU-MGL, TAX and RSV) were saved and visualized to explore the
variations in binding modes of ligands bonded to GLU. Docking results demonstrated
that in GLU-bonded system, compounds TAX and RSV are positioned in such a way to
establish the similar mode of interaction as that observed in MGL-GLU complex (Figure 3D-F). As shown in
Figure 3, GLU-ligand
bonded systems are the main residues that predominantly surround the ligand binding
cavity. Encouragingly, previous study has also reported the same binding cavity as
the preferred ligand binding site for GLU inhibitors.
As depicted in Figure
3D, the benchmark inhibitor of GLU (MGL) establishes several H-bonds with
closely situated amino acid residues R212, D214, Q276, D349 and H348. Similarly, TAX
also remained settled deep inside the active site of GLU, where it may form at least
five H-bond interactions with residues E276, D408, R212, and D214 which reflect the
fact that H-bond interactions in TAX-GLU system are relatively stronger than that of
corresponding interaction of MGL-GLU complex. Likewise, the compound RSV develop a
network of five H-bond interactions with residues H348, R212, D214, D349, and R349
with average distance of 3.0 Å. These results support the higher binding affinity of
RSV towards GLU than TAX and MLG. However, all the ligands demonstrated the
appreciable binding tendency towards GLU. Since, the residues R212 and D214 have
been identified to be involved in making common H-bond interaction in all ligand-GLU
bonded systems; these may be regarded as the key contributor in ligand-GLU complex
formation. In DPP-IV-bonded systems, DPT, TAX and RSV can establish a network of
H-bond interactions (Figure
3G-I). A conserved H-bond interaction between E206 of DPP-4 and compounds
DPT, TAX and RSV has been observed which highlights E206 as crucial residue for
DPP-IV-ligand complex formation. Interestingly, E206 has previously been reported to
make ionic interaction in DPP-IV-ligand complexes. In addition, a pair of conserve
H-bonds can be seen between R669 of DPP-IV and tested leads TAX and RSV. Since, more
than five H-bond interactions were found in TAX- and RSV-DPP-4 systems while only
one H-bond interaction was observed in DPT-DPP-IV system, these variations in
pattern of interactions may explain the superior binding affinity of TAX and RSV
over DPT.MM/PB(GB)SA provides us an opportunity to decompose total binding free energies into
independent components. The MM/PB(GB)SA binding energies were resolved into energy
components behaving independent and revealing deriving forces that are responsible
for variation in affinities of ligands towards GLU, HPA and DPP-4. The vdW and
energy associated with solvation energy (ΔEvdW + ΔGnonpol,sol) increase either from
stacking,
stacking, or vdW contacts play a very essential role in binding of
TAX with HPA (−18.52 kcal•mol−1). The ΔEvdW component for ACB-bonded system is still
slightly higher than (−45.19 kcal•mol−1) than the corresponding value in RSV-bonded
system. In addition, ΔGele contribution in ACB-HPA bonded complex is highest among
all three systems, suggesting that higher binding affinity of ACB than RSV was the
consequence of ΔGele as exhibited in Figure 7A and Table 3. Despite of similar ΔGele
contribution in GLU-bonded systems, the smaller ΔGpred (GB) values for TAX and MGL
bonded systems than GLU-RSV are the consequence of higher favorable
ΔEvdW+ΔGnonpol,sol and energies as exhibited in Figure 7B and Table 4 in TAX-GLU complex. Likewise,
ΔEvdW energy component has found to be the key driving force in DPP-4-ligand complex
formation. In addition, favorable ΔEvdW + ΔGnonpol,sol contribution is the main
driving force for the higher binding affinity of TAX-bonded system as exhibited in
Figure 7C and Table 5.
Table 3.
Comparison Between Binding Free Energies of Standard Compound Acarbose
ACB With TAX and RSV Bond with Alpha-Amylase.
Protein-inhibitor
HPA-ACR
HAP-TAX
HAP-RSV
ΔEvdW
−47.64
−53.62
−56.33
ΔEele
−38.53
−32.86
−21.65
ΔGnonpol,sol
−6.25
−6.38
−6.70
ΔGele,sol(PB)
53.48
53.03
50.62
ΔGele,sol(GB)
47.23
43.39
41.81
ΔEvdW+ΔGnonpol,sol
−52.67
−58.64
−63.03
ΔEele+ΔGele,sol(PB)
14.95
15.14
28.97
ΔEele+ΔGele,sol(GB)
2.45
4.14
7.32
ΔGpred(PB)
−32.69
−38.49
−31.66
ΔGpred(GB)
−45.19
−49.48
−43.05
Table 4.
Comparison Between Binding Free Energies of Miglitol (MGL) With Tested
Compounds TAX and RSV Bond With GLU.
Protein-Inhibitor
GLU-MGL
GLU-TAX
GLU-RSV
ΔEvdW
−36.51
−37.37
−39.99
ΔEele
−12.76
−9.01
−18.71
ΔGnonpol,sol
−4.88
−4.76
−5.43
ΔGele,sol(PB)
32.77
26.39
37.49
ΔGele,sol(GB)
28.66
23.18
29.31
ΔEvdW+ΔGnonpol,sol
41.39
42.13
44.43
ΔEele+ΔGele,sol(PB)
20.01
17.38
18,78
ΔEele+ΔGele,sol(GB)
15.90
14.17
25.65
ΔGpred(PB)
−22.66
−26.58
−25.97
ΔGpred(GB)
−29.81
−31.32
−34.60
Table 5.
Comparison Between Binding Free Energies of Diprotin (DPT) With TAX and
RSV Bond With DPP-IV.
Protein-inhibitor
DPP-DPT
DPP-TAX
DPP-RSV
ΔEvdW
−42.51
−46.16
−46.18
ΔEele
−50.86
−39.62
−27.27
ΔGnonpol,sol
−5.79
−7.68
−5.66
ΔGele,sol(PB)
61.61
60.98
51.58
ΔGele,sol(GB)
58.02
49.11
42.10
ΔEvdW+ΔGnonpol,sol
48.30
53.84
51.84
ΔEele+ΔGele,sol(PB)
10.75
21.36
24.31
ΔEele+ΔGele,sol(GB)
7.34
9.49
24.57
ΔGpred(PB)
−35.07
−30.50
−26.91
ΔGpred(GB)
−40.33
−42.06
−37.66
Comparison Between Binding Free Energies of Standard Compound Acarbose
ACB With TAX and RSV Bond with Alpha-Amylase.Comparison Between Binding Free Energies of Miglitol (MGL) With Tested
Compounds TAX and RSV Bond With GLU.Comparison Between Binding Free Energies of Diprotin (DPT) With TAX and
RSV Bond With DPP-IV.
Conclusion
This study has evaluated the therapeutic potential of bioactive compounds (RSV and
TAX) for the mitigation of DM by investigating the inhibitory impact of bioactive
compounds on HPA, GLU, and DPP-IV activity through in vitro
analysis. We also confirmed the enzyme binding potential of tested bioactive
compounds by employing various computational tools and MD simulations. The results
of this study confirmed that these bioactive compounds are potent inhibitor of HPA,
GLU, and DPP-IV as compared to standards and exhibited high potential to prevent
postprandial hyperglycemia. Resveratrol and taxifolin have the potential to inhibit
the activity of α-amylase, α-glucosidase as result reduce the metabolism of
carbohydrates . Our results also suggest that both bioactive compounds significantly
inhibit the DPP-IV enzymatic activity for glycemic control. Keeping aside the
significant results found from in vitro experiments, the MD
simulations also revealed the high binding affinities of RSV and TAX with HPA as
compared to their other corresponding complex systems. This study will provide full
insight to use bioactive compounds for management of diabetes mellitus irrespective
of already available anti-diabetic drugs to avoid side effects.
Authors: Evandro P Semighini; Jonathan A Resende; Peterson de Andrade; Pedro A B Morais; Ivone Carvalho; Carlton A Taft; Carlos H T P Silva Journal: J Biomol Struct Dyn Date: 2011-04